Improving delivery of tuberculosis preventive therapy for people living with HIV
Prevent TB: Application of Choice Architecture to Implement TB Preventive Therapy in South Africa
This study is trying to find better ways to help people living with HIV in South Africa get the tuberculosis preventive therapy they need to stay healthy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Soweto, Gauteng) |
| Trial ID | NCT04466488 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the delivery of tuberculosis preventive therapy (TPT) among people living with HIV (PWH) in low and middle-income countries, particularly South Africa. It addresses the significant gap between clinical guidelines and actual practice, where less than 20% of eligible patients receive TPT. The study employs innovative strategies, including choice architecture, to improve prescribing behaviors and increase the uptake of TPT in routine care settings. By identifying effective methods to overcome barriers to TPT delivery, the study seeks to significantly reduce TB incidence and mortality among PWH.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are either initiating antiretroviral therapy (ART) or returning for ART re-prescribing.
Not a fit: Patients who are not living with HIV or those who are not eligible for TPT will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a substantial increase in the number of people living with HIV receiving effective tuberculosis preventive therapy, thereby reducing TB-related morbidity and mortality.
How similar studies have performed: Other studies have shown success in improving TPT delivery through various interventions, but this approach using choice architecture is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (≥18 years old) patients initiating ART * Adult (≥18 years old) patients already on ART and coming for ART re-prescribing Exclusion Criteria: * None
Where this trial is running
Soweto, Gauteng
- Perinatal HIV Research Unit — Soweto, Gauteng, South Africa (Recruiting)
Study contacts
- Principal investigator: Christopher Hoffmann, MD, MPH — Johns Hopkins University
- Study coordinator: Christopher Hoffmann, MD, MPH
- Email: choffmann@jhmi.edu
- Phone: 410-614-4257
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.